HEPALIFE TO ACCELERATE RESEARCH ACTIVITIES AND BOLSTER MANAGEMENT AND RESEARCH TEAMS
HepaLife Technologies, Inc. today unveiled plans to accelerate its research
and development activities for the first-of-its-kind artificial liver device based
on the patented PICM-19 cell line, which thus far has demonstrated to be highly
metabolic and ideally suited for incorporation into an artificial liver device.
Recently, positive research findings related to the prolonged survival, density
and function of HepaLife's cell line were presented at the annual National Biomedical
Engineering Society Meeting.